| 1 |
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari et al. · Annals of Oncology
Open access |
20 Oct 2021 |
1,442 |
| 2 |
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner et al. · New England Journal of Medicine
Open access |
31 May 2023 |
780 |
| 3 |
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard et al. · Journal of Clinical Oncology
Open access |
18 May 2022 |
754 |
| 4 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz et al. · The Lancet
Open access |
7 Dec 2022 |
683 |
| 5 |
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet
Open access |
23 Aug 2023 |
475 |
| 6 |
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti et al. · CA A Cancer Journal for Clinicians
Open access |
12 Nov 2021 |
390 |
| 7 |
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology
Open access |
26 May 2022 |
251 |
| 8 |
Efficacy of PI3K inhibitors in advanced breast cancer
B. Verret, Javier Cortés, Thomas Bachelot et al. · Annals of Oncology
Open access |
4 Sep 2019 |
221 |
| 9 |
Enhancing global access to cancer medicines
Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac et al. · CA A Cancer Journal for Clinicians
Open access |
18 Feb 2020 |
206 |
| 10 |
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
José Manuel Pérez-García et al. · The Lancet Oncology
|
18 May 2021 |
166 |
| 11 |
HER2 testing: Current status and future directions
Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Angulo et al. · Cancer Treatment Reviews
Open access |
11 Sep 2013 |
163 |
| 12 |
Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status
Laura García‐Estévez, Javier Cortés, Silvia Pérez et al. · Frontiers in Oncology
Open access |
13 Aug 2021 |
154 |
| 13 |
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Paolo Tarantino, Chiara Corti, Peter Schmid et al. · npj Breast Cancer
Open access |
18 Feb 2022 |
148 |
| 14 |
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
Fátima Cardoso et al. · Nature Medicine
Open access |
21 Jan 2025 |
137 |
| 15 |
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Marta Palafox et al. · Nature Communications
Open access |
7 Sep 2022 |
128 |
| 16 |
Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine
Diogo Alpuim Costa, José Guilherme Nobre, Marta Vaz Batista et al. · Frontiers in Microbiology
Open access |
25 Feb 2021 |
124 |
| 17 |
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Hope S. Rugo, Giampaolo Bianchini, Javier Cortés et al. · ESMO Open
Open access |
Aug 2022 |
123 |
| 18 |
Targeting FGFR pathway in breast cancer
José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino et al. · The Breast
|
20 Nov 2017 |
113 |
| 19 |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer
Antonio Llombart‐Cussac et al. · JAMA Oncology
Open access |
10 Oct 2021 |
109 |
| 20 |
Targeting brain metastases in breast cancer
Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello et al. · Cancer Treatment Reviews
|
16 Dec 2021 |
105 |
| 21 |
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
José Manuel Pérez-García et al. · The Lancet
|
Apr 2024 |
101 |
| 22 |
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Maximilian Johannes Mair, Rupert Bartsch, Émilie Le Rhun et al. · Nature Reviews Clinical Oncology
ReviewOpen access |
21 Apr 2023 |
97 |
| 23 |
Global unmet psychosocial needs in cancer care: health policy
Cristiane Decat Bergerot, Paul B. Jacobsen, William E. Rosa et al. · EClinicalMedicine
Open access |
16 Nov 2024 |
89 |
| 24 |
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Javier Cortés, Kevin Punie, Carlos H. Barrios et al. · New England Journal of Medicine
|
19 Oct 2025 |
85 |
| 25 |
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Yasuo Miyoshi, Yuta Yoshimura, Kenichi Saito et al. · Breast Cancer
Open access |
5 Mar 2020 |
81 |
| 26 |
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
Sara A. Hurvitz et al. · ESMO Open
Open access |
24 Apr 2024 |
78 |
| 27 |
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models
Janice M. Santiago‐O’Farrill, S. John Weroha, Xiaonan Hou et al. · Cancer
Open access |
12 Nov 2019 |
77 |
| 28 |
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Javier Cortés, Patrick Schöffski, Bruce A. Littlefield · Cancer Treatment Reviews
Open access |
20 Aug 2018 |
76 |
| 29 |
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis
Guilherme Nader Marta, Marta Monteforte, Elisa Agostinetto et al. · ESMO Open
ReviewOpen access |
Mar 2024 |
75 |
| 30 |
Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
Andrea Aran, Laia Garrigós, Giuseppe Curigliano et al. · Cancers
Open access |
31 Mar 2022 |
70 |
| 31 |
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer
Ramón Palmero, Álvaro Taus, Santiago Viteri et al. · JCO Precision Oncology
|
11 Jan 2021 |
65 |
| 32 |
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
Débora De Melo Gagliato, Antonio Carlos Buzaid, José Manuel Pérez-García et al. · BioDrugs
|
Sep 2020 |
65 |
| 33 |
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
Viola Salvestrini et al. · Radiotherapy and Oncology
ReviewOpen access |
10 Jul 2023 |
59 |
| 34 |
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Rebecca Alexandra Dent, David W. Cescon, Thomas Bachelot et al. · Future Oncology
Open access |
Aug 2023 |
58 |
| 35 |
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma
Silvia González-Martínez, Belén Perez‐Mies, Irene Carretero‐Barrio et al. · Cancers
Open access |
8 Jul 2020 |
55 |
| 36 |
Translating neoadjuvant therapy into survival benefits: one size does not fit all
Leticia De Mattos‐Arruda, Ronglai Shen, Jorge Sergio Reis-Filho et al. · Nature Reviews Clinical Oncology
ReviewOpen access |
22 Mar 2016 |
55 |
| 37 |
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer
Masato Takahashi, Javier Cortés, Rebecca Alexandra Dent et al. · JAMA Network Open
Open access |
15 Nov 2023 |
54 |
| 38 |
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
Fabrice André, Javier Cortés, G. Curigliano et al. · Annals of Oncology
Open access |
5 Sep 2024 |
48 |
| 39 |
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
Antonio Llombart‐Cussac, Xavier B. Pivot, Laura Biganzoli et al. · The Breast
Open access |
18 Jul 2014 |
47 |
| 40 |
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A. Jacobs et al. · Breast Cancer Research
Open access |
Dec 2019 |
46 |
| 41 |
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med
Open access |
11 Sep 2024 |
45 |
| 42 |
Multi-scale urban data models for early-stage suitability assessment of energy conservation measures in historic urban areas
Aitziber Egusquiza, Iñaki Prieto, José Luis Izkara et al. · Energy and Buildings
Open access |
12 Jan 2018 |
45 |
| 43 |
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Mafalda Oliveira et al. · The Lancet Oncology
|
27 Aug 2024 |
43 |
| 44 |
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Glenn J. Hanna et al. · Cancer Research Communications
Open access |
23 Aug 2023 |
43 |
| 45 |
Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
Mayank A Patel, Isabel Tena, Abhishek Jha et al. · Frontiers in Endocrinology
Open access |
29 Mar 2021 |
42 |
| 46 |
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión et al. · European Journal of Cancer
|
29 Mar 2021 |
41 |
| 47 |
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
David Paul Carbone et al. · ESMO Open
Open access |
29 May 2025 |
40 |
| 48 |
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Rebecca Alexandra Dent, Javier Cortés, Lajos Pusztai et al. · JNCI Journal of the National Cancer Institute
Open access |
21 Jun 2024 |
40 |
| 49 |
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
Serena Di Cosimo, Andrea Malfettone, José Manuel Pérez-García et al. · European Journal of Cancer
Open access |
3 Jun 2020 |
40 |
| 50 |
Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Joan Albanell et al. · Clinical Cancer Research
Open access |
27 Sep 2022 |
39 |